These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 12110993

  • 1. Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors.
    Dekeyne A, Gobert A, Auclair A, Girardon S, Millan MJ.
    Psychopharmacology (Berl); 2002 Jul; 162(2):156-67. PubMed ID: 12110993
    [Abstract] [Full Text] [Related]

  • 2. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
    Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ.
    Pharmacol Biochem Behav; 2002 Apr; 71(4):667-80. PubMed ID: 11888558
    [Abstract] [Full Text] [Related]

  • 3. Discriminative stimulus properties of antidepressant agents: a review.
    Dekeyne A, Millan MJ.
    Behav Pharmacol; 2003 Sep; 14(5-6):391-407. PubMed ID: 14501253
    [Abstract] [Full Text] [Related]

  • 4. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.
    Dekeyne A, Gobert A, Iob L, Cistarelli L, Melon C, Millan MJ.
    Psychopharmacology (Berl); 2001 Nov; 158(2):213-8. PubMed ID: 11702096
    [Abstract] [Full Text] [Related]

  • 5. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test.
    O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I.
    Psychopharmacology (Berl); 2007 Jun; 192(3):357-71. PubMed ID: 17318507
    [Abstract] [Full Text] [Related]

  • 6. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
    Felton TM, Kang TB, Hjorth S, Auerbach SB.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):297-305. PubMed ID: 12644903
    [Abstract] [Full Text] [Related]

  • 7. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors.
    Millan MJ, Dekeyne A.
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):579-93. PubMed ID: 17076935
    [Abstract] [Full Text] [Related]

  • 8. Holtzman and Harlan Sprague-Dawley rats: differences in DRL 72-sec performance and 8-hydroxy-di-propylamino tetralin-induced hypothermia.
    Balcells-Olivero M, Cousins MS, Seiden LS.
    J Pharmacol Exp Ther; 1998 Aug; 286(2):742-52. PubMed ID: 9694929
    [Abstract] [Full Text] [Related]

  • 9. The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat.
    Sokolowski JD, Seiden LS.
    Psychopharmacology (Berl); 1999 Nov; 147(2):153-61. PubMed ID: 10591882
    [Abstract] [Full Text] [Related]

  • 10. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
    Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA.
    Biol Psychiatry; 2000 May 01; 47(9):818-29. PubMed ID: 10812041
    [Abstract] [Full Text] [Related]

  • 11. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
    Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL.
    J Pharmacol Exp Ther; 2001 Aug 01; 298(2):565-80. PubMed ID: 11454918
    [Abstract] [Full Text] [Related]

  • 12. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.
    Dell'Osso B, Palazzo MC, Oldani L, Altamura AC.
    CNS Neurosci Ther; 2011 Dec 01; 17(6):723-32. PubMed ID: 21155988
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms.
    Gannon RL, Millan MJ.
    Psychopharmacology (Berl); 2007 Dec 01; 195(3):325-32. PubMed ID: 17694388
    [Abstract] [Full Text] [Related]

  • 14. The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
    Paterson NE, Balci F, Campbell U, Olivier BE, Hanania T.
    J Psychopharmacol; 2011 Oct 01; 25(10):1357-64. PubMed ID: 20305042
    [Abstract] [Full Text] [Related]

  • 15. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
    Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ.
    J Neurochem; 1997 Dec 01; 69(6):2616-9. PubMed ID: 9375697
    [Abstract] [Full Text] [Related]

  • 16. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.
    Weikop P, Kehr J, Scheel-Krüger J.
    J Psychopharmacol; 2007 Nov 01; 21(8):795-804. PubMed ID: 17984160
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
    Beyer CE, Boikess S, Luo B, Dawson LA.
    J Psychopharmacol; 2002 Dec 01; 16(4):297-304. PubMed ID: 12503828
    [Abstract] [Full Text] [Related]

  • 18. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
    Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, Brocco M.
    J Pharmacol Exp Ther; 2001 Aug 01; 298(2):581-91. PubMed ID: 11454919
    [Abstract] [Full Text] [Related]

  • 19. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.
    Frazer A.
    J Clin Psychiatry; 2001 Aug 01; 62 Suppl 12():16-23. PubMed ID: 11430614
    [Abstract] [Full Text] [Related]

  • 20. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule.
    O'Donnell JM, Marek GJ, Seiden LS.
    Neurosci Biobehav Rev; 2005 Aug 01; 29(4-5):785-98. PubMed ID: 15893376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.